Industry Explorers Blaze On
Industry Explorers Blaze On is a series of interviews with senior executives who played a historical role in drug discovery and development and are still active in the biopharma industry.
Inside The Culture Transformation Initiative At GSK Vaccines
Here I recount a few of the things I learned as part of a team that, back in 2019, was working on a culture transformation initiative at GSK Vaccines (17,000 worldwide employees).
6 Reasons Why India Is The Future Of Global Production Of APIs
Here is why, in my view, India will be essential to the future of global drug production.
How Can Novel Data Registries Inform The Development Of New Medicines, Or Improve Patient Care?
See the answer from Lisa Conte, founder, president, and CEO of Jaguar Health.
Tiptoeing Toward A Cure For Type 1 Diabetes
In working on this month’s cover story, which features Imagine Pharma, a preclinical stage biotech based in Pittsburgh, it was hard not to get swept up in the enthusiasm and promise of the company’s autologous cell therapy treatment for Type 1 diabetes (T1D).
Companies To Watch: CytoAgents
CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.
Your New Book Is Pharma And Profits: Balancing Innovation, Medicine And Drug Pricing. What Is Most Often Overlooked In Political Discussions About Drug Prices?
See the answer from John Lamattina, a senior partner at PureTech Health.
What Has Changed With The R&D Tax Credit?
: The R&D tax credit, an often overlooked and misunderstood opportunity for taxpayers, can be used to offset the cost of drug discovery.
How Can Company Leaders Maintain Commercial Momentum With Marketed Products Without Losing Focus On New Drug Development Programs?
See the answer from Tim Wright, CEO of MiMedx.
Why Life Science Firms Need Tech Specialists On Boards
Often, cybersecurity is not on the agenda for many board meetings, despite it being one of the top risks an organization can face. And many boards lack a technology lead with the insight and understanding to advise on how the company can use technology and protect itself from potential cyber breaches.
The Unsexy But Essential Side Of AI In Life Sciences
The promise of AI depends on fundamentals that can’t be skipped or short-cut. It takes founda-tional work and investments in data model development, standards, governance, and processes to deliver on AI’s potential.
BEYOND THE PRINTED PAGE
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.
LIFE SCIENCE LEADER BLOGS
The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.
Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.